(Q38525018)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

review article

1 reference

title

CAR T-cell therapy: toxicity and the relevance of preclinical models (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Milena Kalaitsidou

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Gray Kueberuwa

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

Antje Schütt

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

publication date

1 January 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

487-497

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity

17 February 2020

cites work

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Building better chimeric antigen receptors for adoptive T cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Design and development of therapies using chimeric antigen receptor-expressing T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Engineered T cells for cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Treating cancer with genetically engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

The basic principles of chimeric antigen receptor design

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Of CARs and TRUCKs: chimeric antigen receptor (CAR) T cells engineered with an inducible cytokine to modulate the tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Targeted immunotherapy of cancer with CAR T cells: achievements and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Engineering T cells for cancer: our synthetic future

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Trafficking of CAR-engineered human T cells following regional or systemic adoptive transfer in SCID beige mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Potential limitations of the NSG humanized mouse as a model system to optimize engineered human T cell therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Humanized NOD-SCID IL2rg–/– mice as a preclinical model for cancer research and its potential use for individualized cancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Monoclonal antibody-induced cytokine-release syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

21 January 2018

The tumor lysis syndrome

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Natural expression of the CD19 antigen impacts the long-term engraftment but not antitumor activity of CD19-specific engineered T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

CAR mechanics: driving T cells into the MUC of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

NY-ESO-1: review of an immunogenic tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

MAGE-A family: attractive targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Differential role of Th1 and Th2 cytokines in autotoxicity driven by CD19-specific second-generation chimeric antigen receptor T cells in a mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Tumor ablation by gene-modified T cells in the absence of autoimmunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Mice as clinically relevant models for the study of cytochrome P450-dependent metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Preclinical in vivo modeling of cytokine release syndrome induced by ErbB-retargeted human T cells: identifying a window of therapeutic opportunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Design of a phase I clinical trial to evaluate intratumoral delivery of ErbB-targeted chimeric antigen receptor T-cells in locally advanced or recurrent head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Treatment of malignant pleural mesothelioma by fibroblast activation protein-specific re-directed T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

CARbodies: Human Antibodies Against Cell Surface Tumor Antigens Selected From Repertoires Displayed on T Cell Chimeric Antigen Receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Isolation of tumor antigen-specific single-chain variable fragments using a chimeric antigen receptor bicistronic retroviral vector in a Mammalian screening protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Treatment of advanced leukemia in mice with mRNA engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

Paths to stemness: building the ultimate antitumour T cell.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FIMT.14.123

21 January 2018

Identifiers

DOI

10.2217/IMT.14.123

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26065475%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

1 reference